The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis

The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis

To date, no psychotropic medication has shown to effectively halt progression to psychosis among individuals at Clinical High-Risk for psychosis (CHR), fueling the search for novel therapeutic agents. Recent evidence supports Palmitoylethanolamide (PEA) signaling as a potential psychosis biomarker,...

Full description

Saved in:
Bibliographic Details
Main Authors: Riccardo Bortoletto, Marco Garzitto, Fabiana Piscitelli, Stefano Fornasaro, Claudia Scipioni, Orietta Sepulcri, Martina Fabris, Francesco Curcio, Matteo Balestrieri, Marco Colizzi
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Brain Sciences
Subjects:
schizophrenia
cannabidiol
nutraceuticals
prevention
transition-age psychiatry
Online Access:https://www.mdpi.com/2076-3425/14/12/1230
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-3425/14/12/1230

Similar Items